APLM (Apollomics Inc. Class A) stock: $23.50, $68.1M market cap, $3.3M cash, $64.8M EV, $56.4M fully diluted market cap. Lead program: APL-101 Oral Capsules (Solid Tumors), Phase 2. Data from Fully Diluted's biotech stocks database.
Share price
$23.50
Market cap
$68.1M
Cash
$3.3M
Enterprise value
$64.8M
Balance sheet
Cash
$3.3M
Debt
$0.0M
Net cash
$3.3M
Enterprise value
$64.8M
Basic shares
2.9M shares
Fully diluted shares
2.4M shares
Fully diluted market cap
$56.4M
Cash per share
$1.13
Cash figures as of 2025-12-31. Database snapshot: 2026-09-22.
Price history
Loading APLM daily closes…
Loading price history…
Pipeline assets
vebreltinib
Stage not disclosed · Active
Target c-Met
Status note Filing identifies vebreltinib as the most advanced / lead product candidate and notes the company has obtained orphan drug designation for it. Phase, indication, target, and modality not stated in the filing excerpts.
Per-asset detail extracted from the 20-F filed 2026-04-24. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 1 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.